These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38473991)

  • 1. Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells.
    Anestopoulos I; Paraskevaidis I; Kyriakou S; Giova LE; Trafalis DT; Botaitis S; Franco R; Pappa A; Panayiotidis MI
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
    Julia E; Salles G
    Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
    Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
    Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
    Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
    Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.
    Mondello P; Ansell SM
    Expert Opin Pharmacother; 2022 Feb; 23(3):295-301. PubMed ID: 34904909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
    Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
    Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
    Fu H; Cheng L; Sa R; Jin Y; Chen L
    J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
    Dockerill M; Gregson C; O' Donovan DH
    Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
    Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
    Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
    Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
    Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
    Zauderer MG; Szlosarek PW; Le Moulec S; Popat S; Taylor P; Planchard D; Scherpereel A; Koczywas M; Forster M; Cameron RB; Peikert T; Argon EK; Michaud NR; Szanto A; Yang J; Chen Y; Kansra V; Agarwal S; Fennell DA
    Lancet Oncol; 2022 Jun; 23(6):758-767. PubMed ID: 35588752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
    Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
    Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway.
    Fu M; Wang Y; Ge M; Hu C; Xiao Y; Ma Y; Gou S
    Bioorg Med Chem Lett; 2024 Nov; 113():129968. PubMed ID: 39293534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
    Qi L; Lindsay H; Kogiso M; Du Y; Braun FK; Zhang H; Guo L; Zhao S; Injac SG; Baxter PA; Su JM; Xiao S; Erickson SW; Earley EJ; Teicher B; Smith MA; Li XN
    Lab Invest; 2022 Feb; 102(2):185-193. PubMed ID: 34802040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and pharmacokinetics of tazemetostat.
    Orleni M; Beumer JH
    Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
    Wu D; Zeng X; Zhao Y; Qin M; Gong P
    Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
    Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
    Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.